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Abstract
Although a genetic basis of depression has been well established in twin studies, identification of genome-wide significant
loci has been difficult. We hypothesized that bivariate analyses of findings from a meta-analysis of genome-wide association
studies (meta-GWASs) of the broad depression phenotype with those from meta-GWASs of self-reported and recurrent
major depressive disorder (MDD), bipolar disorder and schizophrenia would enhance statistical power to identify novel
genetic loci for depression. LD score regression analyses were first used to estimate the genetic correlations of broad
depression with self-reported MDD, recurrent MDD, bipolar disorder and schizophrenia. Then, we performed four bivariate
GWAS analyses. The genetic correlations (rg ± SE) of broad depression with self-reported MDD, recurrent MDD, bipolar
disorder and schizophrenia were 0.79 ± 0.07, 0.24 ± 0.08, 0.53 ± 0.09 and 0.57 ± 0.05, respectively. From a total of 20
independent genome-wide significant loci, 13 loci replicated of which 8 were novel for depression. These were MUC21 for
the broad depression phenotype with self-reported MDD and ZNF804A, MIR3143, PSORS1C2, STK19, SPATA31D1, RTN1
and TCF4 for the broad depression phenotype with schizophrenia. Post-GWAS functional analyses of these loci revealed
their potential biological involvement in psychiatric disorders. Our results emphasize the genetic similarities among different
psychiatric disorders and indicate that cross-disorder analyses may be the best way forward to accelerate gene finding for
depression, or psychiatric disorders in general.
Introduction
A depressive disorder is among the leading causes of
morbidity and disability [1], and it is caused by a combi-
nation of genetic and environmental factors [2]. The genetic
basis of depression is established by twin and family studies
with heritability estimates ranging from 31 to 42% [3].
However, identification of genetic loci has turned out to be
difficult, although more recent studies have started to be
successful. Two loci were replicated based on 180,866
individuals in a meta-analysis combining two case–control
studies on major depressive disorder (MDD) with UK
Biobank data on a two-item measure of depressive symp-
toms [4]. A recent genome-wide association study (GWAS)
that utilized online self-report data from 75,607 individuals
reporting a clinical diagnosis or treatment of MDD and
231,747 controls, obtained through the personal genetics
company 23andMe, Inc., identified 15 loci for MDD in a
European ancestry population [5]. The CONVERGE con-
sortium studied 5303 Han Chinese women with recurrent
MDD and 5337 controls and identified two loci, near the
SIRT1 gene and in an intron of the LHPP gene [3]. Direk
et al. [6] performed a joint analysis of the depressive
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symptoms GWAS meta-analysis (meta-GWAS) from the
CHARGE consortium [7] and the MDD meta-GWAS from
the Psychiatric Genomics Consortium (PGC) [8] involving
70,017 subjects. They discovered one genome-wide sig-
nificant locus mapping to the FHIT gene for this broad
depression phenotype [6]. Finally, the PGC MDD working
group recently conducted a very large meta-GWAS in
130,664 MDD cases and 330,470 controls, and identified 44
independent loci [9].
Both MDD and symptoms of depression overlap with
bipolar disorder and schizophrenia, and the diagnostic
boundaries are sometimes difficult to define [10, 11]. For
example, the so-called negative symptoms of schizophrenia
are highly similar to several of the depression criteria
including loss of interest, psychomotor retardation and low
energy. Moreover, there is a significant overlap in the
genetic risk of these psychiatric disorders. A substantial
genetic correlation (rg ± SE) was reported between MDD
and schizophrenia (0.43 ± 0.06) and between MDD and
bipolar disorder (0.47 ± 0.06) [12]. Also, a bioinformatic
analysis of the PGC data demonstrated that MDD, bipolar
disorder and schizophrenia share common biological path-
ways [13] and the latest PGC MDD GWAS showed sig-
nificant bi-directional single-nucleotide polymorphism
(SNP) effects in Mendelian randomization analyses
between MDD and schizophrenia suggesting bi-directional
causality [9].
Given these substantial phenotypic and genetic associa-
tions [12, 13], it can be argued that bipolar disorder and
schizophrenia have a “depression” component that can be
leveraged in bivariate analyses of depression with these
other two psychiatric disorders to improve the power of gene
discovery. The enhanced statistical power gained
from combining data from related psychiatric disorders was
recently illustrated by applying the bivariate genomic relat-
edness matrix restricted maximum likelihood (GREML)
method implemented in GCTA software [12, 14, 15]
followed by fitting multinomial logistic regression models
that successfully identified genetic loci within the CAC-
NA1C, CACNB2 and ITIH3 genes, shared between the major
psychiatric disorders [15]. However, these methods require
the raw genotype and phenotype data of very large sample
sizes [15, 16]. Recently proposed methods such as the
bivariate linkage disequilibrium (LD) score regression [17]
and bivariate meta-GWAS methods that rely on summary
statistics from previous GWAS findings [18, 19] provide
promising alternatives to estimate genetic correlations and
subsequently identify shared genetic loci. These methods
can be applied to (publicly) available data from large sam-
ples. In this study, we conducted four consecutive bivariate
meta-analyses combining our recent meta-GWAS on the
broad depression phenotype (depressive symptoms com-
bined with MDD diagnosis) [6] with recent meta-GWASs
on self-reported MDD [5], recurrent MDD [3], bipolar dis-
order [20] and schizophrenia [21] with the aim to identify
novel genetic variants for depression. Genome-wide
significant SNPs from the four bivariate GWAS analyses
were replicated using UK Biobank results for broad
depression [22].
Materials and methods
We performed four consecutive bivariate analyses of the
meta-GWASs of the broad depression phenotype [6], with
online self-reported MDD [5], recurrent MDD [3], bipolar
disorder [20] and schizophrenia [21]. The summary statis-
tics of the GWAS results for self-reported MDD were
provided by 23andMe on request and those for recurrent
MDD, bipolar disorder and schizophrenia were available
online (for details, see the Supplementary Materials and
web resources).
Statistical analyses
First, genetic correlations were estimated followed by a
series of four bivariate meta-GWAS analyses. We also
followed up our findings by annotating the genome-wide
significant lead SNPs and conducting post-GWAS analysis
as described below.
Step 1: Genetic correlation analyses
We applied the bivariate LD score regression method
[17, 23] to estimate genetic correlations of the broad
depression phenotype with self-reported MDD, bipolar
disorder and schizophrenia, respectively. Genetic correla-
tions summarize the genome-wide average effects of
pleiotropy at shared loci [24]. This method relies on the LD
score, provided together with the LDSC software and meta-
GWAS summary statistics. The meta-GWAS summary
statistics were obtained from the discovery stage meta-
analyses of GWASs for the broad depression phenotype [6],
self-reported MDD [5], bipolar disorder [20] and schizo-
phrenia [21], while the LD scores were computed using the
1000 Genomes data of Europeans within a window size of
±1Mb as described by Bulik-Sullivan et al. [17]. We used
Popcorn for trans-ancestry estimation of the genetic corre-
lation between our broad depression phenotype and recur-
rent MDD in the Chinese sample [25].
Step 2: Bivariate meta-analyses of genome-wide
association analyses
A series of four bivariate meta-analyses were performed by
combining meta-GWAS data of the broad depression
A. T. Amare et al.
phenotype with self-reported MDD, recurrent MDD, bipolar
disorder and schizophrenia, respectively. We chose to do a
series of bivariate analyses rather than a single multivariate
analysis since the latter would unnecessarily focus the
discovery of loci on the overlapping variance among all
phenotypes studied. Analyzing combinations of two phe-
notypes at a time (i.e., the broad depression phenotype with
(i) self-reported MDD (ii) recurrent MDD; (iii) bipolar
disorder; and (iv) schizophrenia, respectively) should cap-
ture more shared variance thereby facilitating the identifi-
cation and interpretation of novel loci for the broad
depression phenotype. In this study, we applied a powerful
bivariate GWAS analytical method using summary statistics
from GWAS studies [26]. Our method takes into account
the phenotypic correlations among dependent variables
(phenotypes). This is in contrast to a classical (random-
effect and fixed-effect) meta-analysis, in which the pheno-
typic correlations are not taken into account. We applied
both the well-established O’Brien’s (OB) method and our
own direct linear combination of dependent test statistics
(dLC) approach [18, 19] as implemented in the C++ eLX
package. The OB method and the dLC approach [18, 19]
combine univariate meta-GWAS effect estimates (beta
coefficients or Z-scores) of each SNP and yield a combined
significance level based on the bivariate analysis. Power
of these methods compares favorably to other popular
multivariate methods such as that described by Porter
and O'Reilly [27]. More details can be found elsewhere
[18, 19, 26, 28].
In the bivariate meta-analyses, the full set of GWAS
results was used to estimate variance–covariance matrices
of test statistics. We combined the Z-scores of each SNP for
the broad depression phenotype [6] with the Z-scores of: (i)
self-reported MDD, (ii) recurrent MDD, (iii) bipolar dis-
order and (iv) schizophrenia. The analyses generate two test
statistics and associated p values, one for the OB method
and the other for the dLC method. Statistical significance of
the bivariate association was determined based on the
smaller of the two p values. The results were considered
genome-wide significant if: (i) the p value for the bivariate
analysis reached genome-wide significance (p < 5 × 10–8);
(ii) the bivariate p value was one order of magnitude smaller
than the univariate p-values of both analyzed phenotypes;
(iii) the univariate meta-GWAS effects were at least nom-
inally significant with a p < 0.001; and (iv) were in the same
direction. For each bivariate GWAS analysis, only one
independent lead SNP per locus was reported. Nearby SNPs
in LD (r2 > 0.10) with the lead SNP were considered
dependent and belonging to the same locus.
Step 3: Bivariate negative control GWAS analyses
See Supplementary Materials.
Step 4: Replication of genome-wide significant loci in UK
Biobank
Genome-wide significant SNPs from the four bivariate
GWAS analyses were replicated using UK Biobank results
for broad depression [22] and subsequently meta-analyzed
by the dLC approach using the genome-wide summary
statistics [26]. SNPs were considered replicated if: (i)
1-sided p < 0.05, (ii) the effect was directionally consistent
and (iii) the combined discovery and replication meta-
analysis p value was more significant than its corresponding
bivariate GWAS. Additionally, we performed a lookup of
our genome-wide significant SNPs for probable MDD and
ICD-coded MDD [22].
Step 5: Post-GWAS analyses
We used the post-GWAS pipeline reported by Vaez et al. [29]
to annotate findings of our replicated SNPs in combination
with those of established depression loci from the literature
[4–6, 9]. The analyses approach includes in silico sequencing,
in silico lookup of associations with other phenotypes in the
GWAS catalog [30], expression quantitative trait loci analysis
and functional network and enrichment analysis. Addition-
ally, DEPICT [31] was used to prioritize genes, identify gene
sets and evaluate tissue enrichments using results of the four
bivariate GWAS with p < 1 × 10–5 as input (see Supplemen-
tary Materials for details).
Results
Broad depression phenotype with self-reported
MDD
The genetic correlation (rg ± SE) between the broad depres-
sion phenotype and self-reported MDD in the 23andMe data,
calculated using the LD Score regression method, was
0.79 ± 0.07 and highly significant (p= 5.70 × 10–28). In the
bivariate meta-analyses of the broad depression phenotype
and self-reported MDD, three loci (NEGR1, MAT2B,
MUC21) reached genome-wide significance and all were
replicated.MUC21 is novel for depression (Fig. 1a, Table 1,
Supplementary Table 1, Supplementary Figure 1).
Broad depression phenotype with recurrent MDD
The genetic correlation between the broad depression pheno-
type and recurrent MDD was 0.24 ± 0.08 (p= 1.71 × 10–59).
In the bivariate meta-GWAS of broad depression phenotype
and recurrent MDD, the PLEK2 locus reached genome-wide
significance (p= 3.05 × 10–10) but was not replicated (Fig. 1b,
Table 1, Supplementary Table 1).
Bivariate genome-wide association analyses of the broad depression phenotype combined with major. . .
Broad depression phenotype with bipolar disorder
The genetic correlation between the broad depression pheno-
type and bipolar disorder was 0.53 ± 0.09 (p= 5.14 × 10–10).
The bivariate meta-GWAS analysis identified three loci
(RPRD2, ITIH3, CACNA1C) of which ITIH3 replicated
(Fig. 1c, Table 1, Supplementary Table 1, Supplementary
Figure 1). The ITIH3 locus was previously reported [15].
Broad depression phenotype with schizophrenia
The genetic correlation of the broad depression phenotype
with schizophrenia was 0.57 ± 0.05 (p= 1.61 × 10–28). In
the bivariate meta-GWAS analysis with schizophrenia, 16
loci reached bivariate genome-wide significance of which
10 replicated (ZNF804A, ITIH3, FHIT, MIR3143,
PSORS1C2, STK19, SPATA31D1, RTN1, BAG5, TCF4)
and 6 did not (MATN1, AGBL4, VPS45, TSNARE1, CAC-
NA1C, ZCCHC14) (Fig. 1d, Table 1, Supplementary
Table 1, Supplementary Figure 1). Three replicated loci
were previously reported (ITIH3 [15], FHIT [6], BAG5 [9]),
but the other seven (ZNF804A, MIR3143, PSORS1C2,
STK19, SPATA31D1, RTN1, TCF4) were novel for
depression. Although the TCF4 locus was previously
reported by Wray et al. [9], our top SNP is an independent
signal (r2= 0.004) at this same locus (Supplementary Fig-
ure 1). For the ITIH3 locus, the same SNP was found as for
the bivariate GWAS with bipolar disorder (Fig. 1c, d,
Table 1).
Bivariate negative control GWAS analyses
Bivariate LD score regression confirmed that none of the six
control outcomes showed a significant genetic correlation.
In bivariate GWASs we observed a maximum of only 2
genome-wide significant loci with broad depression: 0 for
femoral neck and lumbar spine bone mineral density, 1 for
age-related macular degeneration, and 2 for forearm bone
mineral density, breast and prostate cancer (Supplementary
Table 2). Thus, from six control phenotypes, we identify
seven genome-wide significant findings, indicating a false
positive rate of approximately 1 locus per bivariate analysis.
Post-GWAS analysis
In silico sequencing analysis
Of the total of 13 replicated loci, 2 genome-wide significant
index SNPs (gSNPs) were in LD (r2 > 0.50) with 10 non-
synonymous SNPs (nsSNP), 9 of which were in LD with
rs2535629 (ITIH3) and located in 7 different genes, 3 of
which belonged to the inter-alpha-trypsin inhibitor heavy
chain gene family (ITIH1, ITIH3, ITIH4). Two nsSNPs,
rs1029871 mapping to NEK4 and rs678 to ITIH1, were
considered ”deleterious” by SIFT and “possibly”, respec-
tively, ”probably damaging” by PolyPhen. The nsSNP
rs437179 located within the SKIV2L gene was in high LD
with the other gSNP rs389883 (STK19) (Table 2).
Fig. 1 Manhattan plots showing the result of bivariate analysis
between the broad depression phenotype and a self-reported MDD;
b recurrent MDD; c bipolar disorder; and d schizophrenia, high-
lighting the loci that showed genome-wide significance (orange). The
−log10 (bivariate p value) is plotted against the physical position of
each SNP on each chromosome. The threshold for genome-wide sig-
nificance (bivariate p value < 5 × 10–8) is indicated by the red dotted
horizontal line
A. T. Amare et al.
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Combining our 13 replicated gSNPs with those of
established depression loci from the literature yielded a total
of 56 gSNPs (Supplementary Material). Together with the 2
gSNPs containing nsSNPs in 8 genes described above, these
56 gSNPs included an additional 4 gSNPs in LD (r2 > 0.50)
with 4 nsSNPs mapping to 4 genes, i.e., a total of 12 genes
containing nsSNPs. Our analyses also revealed 1962 SNPs
that are in high LD (r2 > 0.8) with the 56 gSNPs which map
to 70 genes (Supplementary Table 3). The 12 genes con-
taining nsSNPs in combination with the latter 70 genes in
high LD, genes closest to the 56 gSNPs and their expression
quantitative trait locus (eQTL) genes (Supplementary
Table 4) were used in the functional network and enrich-
ment analysis described below.
In silico lookup of GWAS associations
This analysis returned a number of psychiatric and somatic
traits and diseases (Supplementary Table 5).
eQTL analysis
Table 3 shows the findings from the cis-eQTL analysis of
our 13 replicated gSNPs. We observed a total of 34 genes
that were cis-eQTLs in the three databases, 11 in BRAI-
NEAC, 14 in GTEx and 16 in the Westra et al. [32] per-
ipheral blood database. Six of the 34 genes (ITIH4, GNL3,
PRSS16, SKIV2L, XRCC3 and KLC1) had eQTLs in at least
two of the three databases. Of these genes, ITIH4 and GNL3
also contain nsSNPs in LD with rs2535629 (Table 2).
Interestingly, SKIV2L is an eQTL for rs389883, which was
also in high LD with a nsSNP in this gene (Table 2).
Functional network and enrichment analysis
Functional network and enrichment analysis that included all
four prioritized gene sets (see Supplementary Materials for
details) showed enrichment of Gene Ontology (GO) terms
involved in the Ras superfamily, the Rab family and GTPase
activity, as well as terms involved in the epigenetic machinery
and chromatin function (Supplementary Table 6). If limited to
the closest genes, the enrichment for Ras and Rab protein
functions became even stronger. In addition, terms related to
nervous system development and neuronal differentiation
became significant (Supplementary Table 7). Limiting the
input query genes to those with strong functional evidence
based on coding SNPs and/or eQTLs confirmed the invol-
vement of epigenetic regulation and chromatin function
(Supplementary Tables 8 and 9). Based on the results of the
four bivariate GWASs, DEPICT identified one gene, four
nervous system-related tissues and one gene-set that were
significantly enriched (false discovery rate (FDR) < 0.05). The
bivariate GWAS with schizophrenia yielded enrichment of
three tissues: hypothalamus middle, hypothalamo-
hypophyseal system and neurosecretory systems (Supple-
mentary Figure 2). The one with self-reported MDD showed
enrichment in basal ganglia (Supplementary Figure 3). The
identified gene (SMARCA2) and gene-set (SWI/SNF-type
complex) provide converging evidence in line with the
involvement of epigenetic regulation and chromatin function
because the encoded protein is part of the large ATP-
dependent SWI/SNF chromatin remodeling complex.
Discussion
This study combined a GWAS of the broad depression
phenotype with the GWAS results of self-reported MDD,
recurrent MDD, bipolar disorder and schizophrenia and
found substantial genetic correlations with self-reported
MDD (0.79), bipolar disorder (0.53) and schizophrenia
(0.57), and a more moderate but still highly significant
trans-ethnic genetic correlation with recurrent depression
(0.24). We identified 20 independent loci in the 4 sub-
sequent bivariate GWASs, of which 13 replicated in the UK
Biobank. Eight of these were novel for depression. In the
bivariate GWAS with self-reported MDD, we reported one
novel genetic locus mapping to MUC21. The bivariate
GWAS with schizophrenia yielded 16 loci (listed in
Table 1), 10 of which replicated, including 7 novel for
depression: ZNF804A, MIR3143, PSORS1C2, STK19,
SPATA31D1, RTN1 and TCF4. Out of the five previously
reported loci, NEGR1 and MAT2B were previously repor-
ted as associated with self-reported MDD [5], FHIT with
broad depression [6], ITIH3 was detected in a cross-disorder
GWAS [15] and finally BAG5 was identified in the recent
PGC meta-GWAS for MDD [9].
In order to prioritize particular genes within the 13
identified loci for their likely causal involvement, we per-
formed a series of post-GWAS analyses investigating
whether our lead SNPs were in high LD with coding SNPs,
were associated with gene expression in blood or brain or
had previously been reported in the literature to be asso-
ciated with similar or other complex traits. These analyses
yielded a number of candidates with strong evidence for
their functional involvement in the nervous system and
brain development. Thus, they may be involved in the
pathogenesis of psychiatric disorders including depression
(see Supplementary Materials).
One example is the inter-alpha-trypsin inhibitor heavy
chain gene family (ITIH1, ITIH3, ITIH4), which has been
associated with major psychiatric disorders including MDD
[15], bipolar disorder [15, 33] and schizophrenia [15, 33].
We confirmed their likely functional involvement based on
LD with nsSNPs for ITIH1, ITIH3 and ITIH4, whereas
ITIH4 was an eQTL in both blood and brain across all three
A. T. Amare et al.
databases. Furthermore, LD with a nsSNP pointed to
SKIV2L as a likely causal candidate for depression, addi-
tionally supported by eQTL evidence in blood and brain.
For the functional network and enrichment analyses, we
included all our prioritized genes based on our replicated
SNPs in combination with those of established depression
loci from the literature. The findings showed enrichment of
GO terms involved in the Ras superfamily, the Rab family
and GTPase activity. The Rab protein family is involved in
clathrin-mediated endocytosis, a mechanism governing
cellular membrane and protein trafficking, which has been
implicated in the pathophysiology of psychotic disorders
through synaptic dysfunction, white matter changes and
aberrant neurodevelopment [34]. Thus, the current evidence
also implicates depression, in line with earlier evidence that
activators of the Ras superfamily of GTPases, Raf1 and B-
Raf, are dysregulated in postmortem brains of suicide cases
[35]. Other enriched GO terms highlighted the epigenetic
machinery and chromatin function as well as nervous sys-
tem development and neuronal differentiation. These latter
enrichments were confirmed by our DEPICT analyses and
by post-GWAS results from the most recent PGC MDD
meta-GWAS [9].
An important asset of our study is that we used most of
the currently available data and exploited the biological
pleiotropy among psychiatric disorders [36] to identify
eight novel loci for broad depression replicated in a large
population-based cohort. On the other hand, one potential
limitation of our four bivariate analyses is that they do not
allow identification of loci that are specific for depression.
We showed that our strategy of combined analysis of the
broad depression phenotype with correlated psychiatric
Table 3 eQTL analysis results for the 13 replicated gSNPs
SNP CHR BP Allele eQTL lookup in three databases
Westra et al. [32],
FDR < 0.05
BRAINEAC, p < 1 × 10–5 GTEx, FDR < 0.05
rs2535629 3 52833219 G/A SPCS1, ITIH4 ITIH4, GNL3, GLT8D1,
SNORD19B
ITIH4, PPM1M, GNL3
rs911186 6 27150599 A/G HIST1H2BK,
PRSS16
ZNF389, BTN2A1,BTN2A2 PRSS16, ZNF204P
rs9368649 6 30938883 A/G VARSL
rs1265099 6 31105413 G/A HCG27 PSORS1C2 C4A
rs389883 6 31947460 G/T DOM3Z, HSPA1B,
SKIV2L
NFKBIL1 CYP21A1P, HLA-C, HLA-DRB5, WASF5P,
XXbac-BPG248L24.12, SKIV2L, HLA-DRB1
rs2182139 14 60149233 C/T RTN1, C14orf100
rs4906335 14 104021141 C/A BAG5, XRCC3,
KLC1, EIF5, CKB
KLC1,C14orf153 XRCC3
Genes with eQTLs in multiple databases are in bold
Table 2 Nonsynonymous SNPs in LD (r2 ≥ 0.50) with the replicated gSNPs
gSNP Nonsynonymous SNP
linked with gSNPs
CHR BP A1 A2 LD (r2) Gene
rs2535629 rs4434138 3 52556890 A G 0.56 STAB1
rs11177 3 52721305 G A 0.75 GNL3
rs2289247 3 52727257 G A 0.73 GNL3
rs6617 3 52740182 C G 0.73 SPCS1
rs1029871a, b 3 52797634 G C 0.75 NEK4
rs678a, c 3 52820981 A T 0.84 ITIH1
rs1042779 3 52821011 A G 0.84 ITIH1
rs3617 3 52833805 C A 0.64 ITIH3
rs4687657 3 52852538 G T 0.55 ITIH4
rs389883 rs437179 6 31929014 A C 0.99 SKIV2L
aDeleterious (SIFT)
bPossibly damaging (PolyPhen)
cProbably damaging (PolyPhen)
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disorders or traits was most successful for the largest
sample sizes (those for self-reported MDD and schizo-
phrenia). In addition, although not the primary aim of our
study, we also identified one novel locus for bipolar
disorder and nine for schizophrenia (Table 1), although
these need to be replicated. One limitation of our
approach of using GWAS summary statistics in our
analyses is that we could not explore potential hetero-
geneity of our results by stratifying, for example, for age
and sex. However, it would be interesting for future
studies to explore whether effects of established loci,
including those we have now replicated using the UK
Biobank results, may vary according to age, sex or even
depressive subtype. Another point of discussion may be
our strategy to avoid the identification of false positive
loci. We took the following precautions: in the bivariate
GWAS discovery phase we applied a strict significance
criterion of p < 5 × 10–8 and demanded a nominal and
directionally consistent effect in both contributing GWAS
samples (p < 0.001). In the replication phase, a SNP was
only considered replicated if a one-sided test was nom-
inally significant (pone sided < 0.05), i.e., the effect was
directionally consistent, and the combined meta-analysis
of the discovery and replication yielded a p value more
significant than the corresponding bivariate p value.
Although these are sound precautions similar to those
applied in previous recent work [37], it can still be argued
that the replication phase may have yielded 1–2 loci
merely based on chance. Thus, we applied, post-hoc, an
additional FDR analysis to our replication p values.
Reassuringly, all 13 replicated SNPs showed an FDR <
0.05 confirming the appropriateness and strictness of our
replication criteria.
The substantial genetic correlations within depression
(ranging from the mild depression continuum to more
severe recurrent MDD) and across psychiatric disorders
(i.e., bipolar disorder, schizophrenia) suggest that psychia-
tric illnesses may differ, in part, quantitatively rather than
qualitatively from each other, and cross-disorder (dimen-
sional) [24] analysis approaches may be the best way for-
ward. It has even been argued that genetic variants that are
specific to a single diagnostic category are unlikely to exist
and that our reliance on separate diagnoses actually hampers
progress [36]. As evidenced by the results of our study,
cross-disorder analyses yield novel genetic loci and will
extend our understanding of overlapping mechanisms
among the different psychiatric disorders.
Web resources
Recurrent MDD, bipolar disorder and schizophrenia sum-
mary data: http://www.med.unc.edu/pgc/downloads. UK
Biobank depression summary data: https://datashare.is.ed.
ac.uk/handle/10283/3036. Blood eQTL browser: http://
genenetwork.nl/bloodeqtlbrowser. UK Brain Expression
Consortium (UKBEC): http://www.braineac.org/. GTEx:
http://www.gtexportal.org/home/. Ensembl genome brow-
ser: http://www.ensembl.org. DEPICT: www.broadinstitute.
org/depict. Online methods: eLX package: https://sites.
google.com/site/multivariateyihsianghsu/. LDSC software:
https://github.com/bulik/ldsc.
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